Get the Stockscreener App
29.24
3.36%
0.95
After Hours:
29.41
0.17
+0.58%
Faeth Therapeutics Inc stock is traded at $29.24, with a volume of 359.01K.
It is up +3.36% in the last 24 hours and up +27.85% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$28.29
Open:
$28.45
24h Volume:
359.01K
Relative Volume:
4.18
Market Cap:
$753.77M
Revenue:
-
Net Income/Loss:
$-184.46M
P/E Ratio:
-0.2049
EPS:
-142.7277
Net Cash Flow:
$-24.11M
1W Performance:
+3.72%
1M Performance:
+27.85%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$27.93
$31.61
1-Week Range:
$26.57
$31.61
52-Week Range:
$17.50
$37.90
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
29.24 | 729.28M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Faeth Therapeutics Inc Stock (FTH) Latest News
Faeth Therapeutics initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 23, 2026 - marketscreener.com
Faeth Therapeutics Ord Shs (FTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FTH|Faeth Therapeutics Ord Shs|Price:28.290|Chg%:+0.530 - TradingKey
Faeth Therapeutics Adopts Performance-Based Stock Option Plan - TipRanks
Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver - TradingView
Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
Citizens initiates Faeth Therapeutics stock at outperform, $51 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Intuitive Surgical (ISRG) and Faeth Therapeutics (FTH) - The Globe and Mail
Citi Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FTH Reiterated by BTIG -- Price Target Maintained at $55 - GuruFocus
Issuance/retirement of debt (net) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc trading resumes - TipRanks
A Closer Look At Faeth Therapeutics' PIKTOR - RTTNews
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Faeth’s PIKTOR Trial Targets Advanced Breast Cancer With a New Combo Approach - TipRanks
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com UK
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
Faeth Therapeutics Inc Stock (FTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):